Clinical Trial Update: Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating systemic exposure to VP-102 in subjects with molluscum contagiosum completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Molluscum Contagiosum

Drugs mentioned

• VP-102 (cantharidin topical solution)

Snippet

Sponsor: Verrica Pharmaceuticals Inc. | Conditions: Molluscum Contagiosum | Phase 2 | Status: COMPLETED | Results posted: 2021-08-09